United Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by StockNews.com

United Therapeutics (NASDAQ:UTHR) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Other equities research analysts have also issued research reports about the company. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group upped their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. TD Cowen upped their target price on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Bank of America reduced their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. Finally, Oppenheimer increased their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $368.43 on Thursday. The business’s 50 day simple moving average is $350.66 and its 200-day simple moving average is $307.90. The firm has a market capitalization of $16.34 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $377.03.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same period last year, the firm earned $5.24 EPS. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics will post 24.72 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $833,350.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,792 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96. Following the completion of the sale, the chief financial officer now owns 5,884 shares of the company’s stock, valued at approximately $2,093,997.92. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,830 shares of company stock worth $36,010,158 in the last ninety days. Insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its holdings in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after buying an additional 4,100 shares during the last quarter. Comerica Bank boosted its position in United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after buying an additional 9,244 shares during the last quarter. Tri Locum Partners LP purchased a new position in United Therapeutics in the 2nd quarter valued at about $15,959,000. Finally, QRG Capital Management Inc. boosted its position in United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after buying an additional 1,692 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.